Four first-line drugs for NSCLC treatment, osimertinib, gefitinib, erlotinib, and icotinib, were selected according to the NCCN guideline [8] and CSCO guideline.[9] The dose-response curve study demonstrated that the EGFR double mutation in cancer organoids was clearly dose responsive to osimertinib and gefitinib with IC50 values of 1.66 μM and 1.26 μM, respectively; but not sensitive to erlotinib or icotinib (Fig. 4). This evidence concerns the gene EGFR and cancer.